[go: up one dir, main page]

ATE236981T1 - Von menschlichen t-zellen immunodominante epiropen des virus der c-hepatitis - Google Patents

Von menschlichen t-zellen immunodominante epiropen des virus der c-hepatitis

Info

Publication number
ATE236981T1
ATE236981T1 AT94931000T AT94931000T ATE236981T1 AT E236981 T1 ATE236981 T1 AT E236981T1 AT 94931000 T AT94931000 T AT 94931000T AT 94931000 T AT94931000 T AT 94931000T AT E236981 T1 ATE236981 T1 AT E236981T1
Authority
AT
Austria
Prior art keywords
epiropes
human
hepatitis virus
cell immunodominant
amino acids
Prior art date
Application number
AT94931000T
Other languages
English (en)
Inventor
Geert Leroux-Roels
Robert Deleys
Geert Maertens
Original Assignee
Innogenetics Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8214764&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE236981(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Innogenetics Nv filed Critical Innogenetics Nv
Application granted granted Critical
Publication of ATE236981T1 publication Critical patent/ATE236981T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/826—Viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT94931000T 1993-11-04 1994-10-28 Von menschlichen t-zellen immunodominante epiropen des virus der c-hepatitis ATE236981T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP93402718 1993-11-04
PCT/EP1994/003555 WO1995012677A2 (en) 1993-11-04 1994-10-28 Immunodominant human t-cell epitopes of hepatitis c virus

Publications (1)

Publication Number Publication Date
ATE236981T1 true ATE236981T1 (de) 2003-04-15

Family

ID=8214764

Family Applications (3)

Application Number Title Priority Date Filing Date
AT99116672T ATE274578T1 (de) 1993-11-04 1994-10-28 Von menschlichen t-zellen immunodominante epitopen des virus der c-hepatitis
AT99116671T ATE290592T1 (de) 1993-11-04 1994-10-28 Von menschlichen t-zellen immunodominante epitopen des virus der c-hepatitis
AT94931000T ATE236981T1 (de) 1993-11-04 1994-10-28 Von menschlichen t-zellen immunodominante epiropen des virus der c-hepatitis

Family Applications Before (2)

Application Number Title Priority Date Filing Date
AT99116672T ATE274578T1 (de) 1993-11-04 1994-10-28 Von menschlichen t-zellen immunodominante epitopen des virus der c-hepatitis
AT99116671T ATE290592T1 (de) 1993-11-04 1994-10-28 Von menschlichen t-zellen immunodominante epitopen des virus der c-hepatitis

Country Status (11)

Country Link
US (4) US6555114B1 (de)
EP (4) EP0992580B1 (de)
JP (2) JPH09504534A (de)
AT (3) ATE274578T1 (de)
AU (1) AU698878B2 (de)
CA (1) CA2175692A1 (de)
DE (3) DE69434295T2 (de)
DK (2) DK0992580T3 (de)
ES (2) ES2239819T3 (de)
PT (2) PT725824E (de)
WO (1) WO1995012677A2 (de)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE249838T1 (de) 1993-05-12 2003-10-15 Chiron Corp Konserviertes motiv der hepatitis c virus e2/ns1 region
US7070790B1 (en) * 1993-06-29 2006-07-04 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and deduced amino acid sequences of the envelope 1 and core genes of isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods and vaccines
EP0992580B1 (de) * 1993-11-04 2005-03-09 Innogenetics N.V. Von menschlichen T-Zellen immunodominante Epitopen des Virus der C-Hepatitis
US5709995A (en) 1994-03-17 1998-01-20 The Scripps Research Institute Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses
DE69517521T2 (de) * 1994-04-08 2001-03-08 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Rockville Peptid aus dem inneren des hepatitis-c-virus brauchbar für die stimulation cytotoxischer t-lymphocyten und die diagnose des hcv-kontaktes
AU752131C (en) 1997-11-06 2003-12-04 Innogenetics N.V. Multi-mer peptides derived from hepatitis C virus envelope proteins for diagnostic use and vaccination purposes
TR200202213T2 (tr) 1998-04-17 2002-11-21 Innogenetics N.V. İndirgeme ajanlarını kullanarak geliştirilen immünodiagnostik tahliller
WO1999058561A1 (fr) * 1998-05-14 1999-11-18 Pasteur Merieux Serums & Vaccins Mimotopes du virus de l'hepatite c
NZ508812A (en) * 1998-06-12 2002-11-26 Aventis Pasteur Peptides for the prevention or treatment of HIV
NZ528952A (en) * 1998-06-24 2004-09-24 Innogenetics N Particles of HCV envelope proteins: use for vaccination
US7108855B2 (en) 1998-06-24 2006-09-19 Innogenetics N.V. Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
US6685944B1 (en) 1998-08-21 2004-02-03 The United States Of America As Represented By The Department Of Health And Human Services Modified HCV peptide vaccines
DE19908423A1 (de) * 1999-02-26 2000-08-31 Deutsches Krebsforsch An der Entwicklung des ZNS beteiligtes Protein (TP)
AT408721B (de) * 1999-10-01 2002-02-25 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung enthaltend ein antigen
EP1535628B1 (de) * 1999-11-24 2013-07-31 Novartis Vaccines and Diagnostics, Inc. Hbv/hcv virus-ähnliche teilchen
US6858590B2 (en) * 2000-08-17 2005-02-22 Tripep Ab Vaccines containing ribavirin and methods of use thereof
US6680059B2 (en) 2000-08-29 2004-01-20 Tripep Ab Vaccines containing ribavirin and methods of use thereof
US7022830B2 (en) * 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
JP2004522415A (ja) * 2000-09-01 2004-07-29 エピミューン インコーポレーティッド Ｈｌａ結合ペプチドおよびその使用方法
GB0026094D0 (en) * 2000-10-25 2000-12-13 Imp College Innovations Ltd Methods
US7402567B2 (en) * 2000-10-27 2008-07-22 The Regents Of The University Of California Treatment of disease by inducing cell apoptosis
US8129349B2 (en) * 2000-10-27 2012-03-06 The Regents Of The University Of California Treatment of disease by inducing cell apoptosis
US7101561B2 (en) 2000-12-01 2006-09-05 Innogenetics N.V. Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
AU2002252856A1 (en) 2001-04-24 2002-11-05 Innogenetics N.V. Expression of core-glycosylated hcv envelope proteins in yeast
FR2825093B1 (fr) * 2001-05-28 2003-07-18 Bio Merieux Polypeptide reagissant avecles anticorps de patients infectes par vhc et utilisations
FR2825363A1 (fr) * 2001-05-31 2002-12-06 Bio Merieux Polypeptides reagissant avec les anticorps de patients infectes par vhc et utilisations
US7736677B2 (en) * 2001-06-20 2010-06-15 Metaproteomics, Llc Xanthohumol and tetrahydro-isoalpha acid based protein kinase modulation cancer treatment
JP2003064096A (ja) * 2001-08-29 2003-03-05 Mitsubishi Kagaku Bio-Clinical Laboratories Inc Ｃ型肝炎ウイルス特異的細胞障害性ｔ細胞認識エピトープ
GB0126782D0 (en) * 2001-11-07 2002-01-02 Medical Res Council Assay
US20040126395A1 (en) * 2001-12-18 2004-07-01 Geert Maertens Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
WO2003051912A2 (en) * 2001-12-18 2003-06-26 Innogenetics N.V. Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use
US7201904B2 (en) 2002-05-16 2007-04-10 The General Hospital Corporation Epitopes of hepatitis C virus
US8029803B2 (en) * 2002-06-20 2011-10-04 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
US8025873B2 (en) * 2002-06-20 2011-09-27 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
EP1539809A4 (de) * 2002-07-02 2006-03-08 Chiron Corp Hcv-fusionsproteine mit modifizierten ns3-domänen
CA2504711A1 (en) * 2002-11-08 2004-05-21 Innogenetics N.V. Hcv vaccine compositions comprising e1 and ns3 peptides
US20060269562A1 (en) * 2003-01-07 2006-11-30 Christine Bain Polypeptides f' of the hepatitis c virus, t epitopeo, and the diagnostic and therapeutic applications thereof
US8007805B2 (en) * 2003-08-08 2011-08-30 Paladin Labs, Inc. Chimeric antigens for breaking host tolerance to foreign antigens
US7785875B2 (en) 2004-07-03 2010-08-31 Mogam Biotechnology Research Institute Polynucleotide encoding HCV epitopes which can bind to various HLA supertypes, immunogenic composition comprising same and method of inducing an HCV-specific immune response using same
JP2008505636A (ja) * 2004-07-03 2008-02-28 モガム バイオテクノロジー リサーチ インスティチュート Ｈｃｖに有効なｃｔｌ反応を誘導するスーパータイプのエピトープ、これをコードするオリゴヌクレオチド並びにそれらの用途
CU23470A1 (es) * 2004-08-11 2009-12-17 Ct Ingenieria Genetica Biotech Vectores vivos recombinantes y su uso en composiciones farmacéuticas contra el virus de la hepatitis c
EP1797112B1 (de) * 2004-09-29 2010-07-21 The Administrators of the Tulane Educational Fund Inhibitoren des hepatitis-c-virus
WO2006044923A2 (en) * 2004-10-18 2006-04-27 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis c infection
CA2618429A1 (en) * 2005-05-25 2007-03-22 Tripep Ab A hepatitis c virus non-structural ns3/4a fusion gene
BRPI0617330A2 (pt) * 2005-10-13 2011-07-19 Virexx Medical Corp antìgeno quimérico contendo polipeptìdeo do vìrus da hepatite c e fragmento fc para despertar uma resposta imunológica
WO2007149503A2 (en) * 2006-06-20 2007-12-27 Metaproteomics, Llc. Xanthohumol and tetrahydro-isoalpha acid based protein kinase modulation cancer treatment
EP2040745B1 (de) * 2006-06-28 2012-12-05 Statens Serum Institut Expansion des t-zell-repertoirs, um subdominante epitope durch impfung mit antigenen, die als proteinfragmente oder peptidcocktails abgegeben werden, aufzunehmen
WO2009022236A2 (en) 2007-08-16 2009-02-19 Tripep Ab Immunogen platform
ES2303496B1 (es) * 2008-02-21 2009-07-07 Fundacion Para El Estudio De Las Hepatitis Virales Metodo analitico perfeccionado para la deteccion de hepatitis c oculta, aplicaciones del mismo y su correspondiente kit de diagnostico.
WO2009130588A2 (en) * 2008-04-22 2009-10-29 Tripep Ab Immunogen platform
WO2010033841A1 (en) 2008-09-19 2010-03-25 Globeimmune, Inc. Immunotherapy for chronic hepatitis c virus infection
AU2010229675B2 (en) * 2009-03-27 2016-02-25 Academia Sinica Methods and compositions for immunization against virus
WO2010112733A1 (fr) * 2009-03-30 2010-10-07 bioMérieux Support solide de détection du vhc
WO2012033142A1 (ja) 2010-09-08 2012-03-15 学校法人 埼玉医科大学 Ｃ型肝炎ウイルスリポソームワクチン
TWI537385B (zh) 2010-11-04 2016-06-11 中央研究院 產生具簡單醣基化之表面蛋白質之病毒顆粒的方法
AU2011335551B2 (en) 2010-12-02 2016-10-06 Bionor Immuno As Peptide scaffold design
BR112013017488A2 (pt) 2011-01-06 2017-08-01 Bionor Immuno As peptídeos imunogênicos multiméricos e monoméricos
WO2013182661A1 (en) 2012-06-06 2013-12-12 Bionor Immuno As Peptides derived from viral proteins for use as immunogens and dosage reactants
CN105073989A (zh) * 2013-02-19 2015-11-18 国立大学法人神户大学 免疫原性多肽表层表达双歧杆菌
US9790478B2 (en) 2013-03-14 2017-10-17 Abbott Laboratories HCV NS3 recombinant antigens and mutants thereof for improved antibody detection
CN113549148B (zh) * 2013-03-14 2025-11-21 雅培制药有限公司 Hcv核心脂质结合结构域单克隆抗体
JP6505076B2 (ja) 2013-03-14 2019-04-24 アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ Ｈｃｖ抗原−抗体組み合わせアッセイおよびこれに使用するための方法および組成物
WO2015006337A2 (en) * 2013-07-08 2015-01-15 Nanjingjinsirui Science & Technology Biology Corporation Compositions and methods for increasing protein half-life in a serum
CA3037813A1 (en) 2016-09-21 2018-03-29 The Governors Of The University Of Alberta Hepatitis c virus immunogenic compositions and methods of use thereof
CA3093314A1 (en) * 2018-03-16 2019-09-19 The Governors Of The University Of Alberta Hepatitis c virus peptide compositions and methods of use thereof
CN109160942B (zh) * 2018-09-26 2021-06-29 广州市第八人民医院 Hcv包膜蛋白高度保守区域的肽段502-518及其用途
JP2022518488A (ja) * 2019-01-25 2022-03-15 センティ バイオサイエンシズ インコーポレイテッド タンパク質機能を制御するための融合構築物

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5350671A (en) * 1987-11-18 1994-09-27 Chiron Corporation HCV immunoassays employing C domain antigens
US6027729A (en) 1989-04-20 2000-02-22 Chiron Corporation NANBV Diagnostics and vaccines
US5747239A (en) * 1990-02-16 1998-05-05 United Biomedical, Inc. Synthetic peptides specific for the detection of antibodies to HCV, diagnosis of HCV infection and preventions thereof as vaccines
US5639594A (en) * 1990-02-16 1997-06-17 United Biomedical, Inc. Linear and branched peptides effective in diagnosing and detecting non-A, non-B hepatitis
IE911130A1 (en) * 1990-04-04 1991-10-09 Protos Hepatitis c protease inhibitors
US5747339A (en) 1990-06-25 1998-05-05 Research Foundation For Microbial Diseases Of Osaka Non-A, non-B hepatitis virus genomic CDNA and antigen polypeptide
EP0468657A3 (en) * 1990-07-09 1992-02-05 Tonen Corporation Non-a non b hepatitis-specific antigen and its use in hepatitus diagnosis
CA2047792C (en) * 1990-07-26 2002-07-02 Chang Y. Wang Synthetic peptides specific for the detection of antibodies to hcv, diagnosis of hcv infection and prevention thereof as vaccines
CA2049679C (en) * 1990-08-24 2005-06-21 Sushil G. Devare Hepatitis c assay utilizing recombinant antigens
EP0485209A1 (de) * 1990-11-08 1992-05-13 Immuno Japan Inc. Mit Non-A Non-B Hepatitis Virus verwandtes Antigen, Aufspürsysteme für Antikörper, Polynukleotide und Polypeptide
AU648912B2 (en) 1991-06-13 1994-05-05 Dade International Inc. Immunoassay for non-A non-B hepatitis
EP0591431B1 (de) * 1991-06-24 2002-12-11 Chiron Corporation Polypeptide des hepatitis c-virus (hiv)
DE4209215A1 (de) * 1991-07-04 1993-01-07 Boehringer Mannheim Gmbh Hcv peptidantigene und verfahren zur bestimmung von hcv
US5428145A (en) 1991-08-09 1995-06-27 Immuno Japan, Inc. Non-A, non-B, hepatitis virus genome, polynucleotides, polypeptides, antigen, antibody and detection systems
AU2513592A (en) * 1991-08-21 1993-03-16 Abbott Laboratories Hepatitis c assay utilizing recombinant antigens to ns1
ES2182822T3 (es) * 1991-09-13 2003-03-16 Chiron Corp Composiciones de polipeptidos inmunorreactivos del virus de la hepatitis c.
ES2145746T5 (es) * 1991-09-16 2005-04-16 Abbott Laboratories Analisis de deteccion de la hepatitis c.
CA2128896A1 (en) * 1992-02-04 1993-08-05 Douglas J. Jolly Hepatitis therapeutics
ATE364621T1 (de) 1992-03-06 2007-07-15 Innogenetics Nv Hiv-peptide
EP0728764A4 (de) * 1993-10-19 1999-01-20 Ajinomoto Kk Peptide das eine immunantwort gegen hiv unduziert und arzneimittel die esenthaelt zur vorbeugung oder behandlung von aids
EP0992580B1 (de) * 1993-11-04 2005-03-09 Innogenetics N.V. Von menschlichen T-Zellen immunodominante Epitopen des Virus der C-Hepatitis
US5709995A (en) 1994-03-17 1998-01-20 The Scripps Research Institute Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses
US5543657A (en) * 1994-10-07 1996-08-06 International Business Machines Corporation Single layer leadframe design with groundplane capability

Also Published As

Publication number Publication date
EP0992580A2 (de) 2000-04-12
EP0992580A3 (de) 2000-08-09
EP0992581B2 (de) 2011-05-25
US6689368B1 (en) 2004-02-10
ES2197170T3 (es) 2004-01-01
ATE274578T1 (de) 2004-09-15
JPH09504534A (ja) 1997-05-06
JP2004194668A (ja) 2004-07-15
DE69433971T2 (de) 2005-09-08
DE69432475D1 (de) 2003-05-15
DE69434295D1 (de) 2005-04-14
EP0979867A3 (de) 2007-06-13
DE69433971D1 (de) 2004-09-30
ATE290592T1 (de) 2005-03-15
US6555114B1 (en) 2003-04-29
ES2239819T3 (es) 2005-10-01
EP0725824B1 (de) 2003-04-09
CA2175692A1 (en) 1995-05-11
DE69432475T2 (de) 2004-03-04
PT992580E (pt) 2005-07-29
US6613333B1 (en) 2003-09-02
EP0725824A1 (de) 1996-08-14
US20040047877A1 (en) 2004-03-11
DK0992580T3 (da) 2005-07-11
PT725824E (pt) 2003-08-29
WO1995012677A2 (en) 1995-05-11
EP0979867A2 (de) 2000-02-16
EP0992581A3 (de) 2001-03-07
DK0725824T3 (da) 2003-08-11
AU698878B2 (en) 1998-11-12
EP0992581B1 (de) 2004-08-25
DE69434295T2 (de) 2006-02-16
AU7993294A (en) 1995-05-23
WO1995012677A3 (en) 1995-07-27
EP0992581A2 (de) 2000-04-12
EP0992580B1 (de) 2005-03-09

Similar Documents

Publication Publication Date Title
ATE236981T1 (de) Von menschlichen t-zellen immunodominante epiropen des virus der c-hepatitis
ATA257190A (de) Virales polypeptid
DE68929467D1 (de) HIV-2 Varianten
DK0792287T3 (da) Peptidanaloger af humant basisk myelinprotein
DK0523395T3 (da) Seroreaktive områder på proteinerne E1 og E2 i HPV 16
DE69130071D1 (de) Zusammensetzung verwendbar als therapeutisches mittel gegen chronische virale leberkrankheiten
GB8625435D0 (en) Human apolipoprotein ai
DE69715181D1 (de) Peptid der löslichen form von acetylcholinesterase mit aktivität als calciumkanalmodulator
DE69534296D1 (de) Sektretierter E1/E2 Hepatitis C Virus-Komplex erhalten aus C-terminal verkürzten Polypeptiden E1 und E2
SE8801723D0 (sv) Fibronectin binding protein as well as its preparation
ATE143974T1 (de) Peptide des hiv-gag proteins, ihre herstellung und verwendung
DK204588A (da) Humane rhinoviruspeptider, fremgangsmaade til deres fremstilling samt vacciner med inhold af saadanne peptider
ATE205220T1 (de) Hepatitis-a-impfstoff
DE69328488D1 (de) Peptide, analoge und ihre mischungen zur detektion und erzeugung von antikörpern gegen die e1 und e2 proteine des rubella virus
DK0453719T3 (da) Bacteriocinpeptid
ES2059801T3 (es) Nuevas linfoquinas, secuencias de adn que codifican para estas linfoquinas, y composiciones farmaceuticas conteniendo estas linfoquinas.
EP0637631A3 (de) Hoch effiziente Expression eines Polypeptids, das eine modifizierte preS1-Region des grossen Hepatitis B-Virus-Antigens enthält.
ITFI920071A0 (it) Antigeni ricombinanti proteici ad aumentata immunogenicita' contenenti il peptide rappresentato dalla sequenza vogeesndk
IT1270941B (it) Peptidi di hcv e loro usi.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0725824

Country of ref document: EP

RZN Patent revoked